Work with the Most Trusted CRO and Proceed with Your Lead Antibody with Confidence
Integrated Services for Therapeutic Antibodies.
We support you during the most critical step – the decision for the final lead candidate. We provide quality data including preformulation and storage stability studies to enable you to choose the most promising lead, know its weaknesses and risks, and prepare for preclinical and clinical development.
The result is a streamlined path with high-quality data, faster timelines, and confident, smooth and speedy progression on the path to clinical development.
Our Integrated Antibody Development Services
Small-Scale Antibody Production
- Cloning and expression
- Purification and quality control (QC)
- 15-25 days turnaround time
- Low and high throughput
Screening Phase
- 100s of molecules (20 µg per molecule)
- Binding screens with purified target protein and target cells
- Developability screens
- Affinity ranking
Lead Selection
- 10s of molecules (500 µg per molecule)
- Comprehensive kinetics with purified protein
- EC50 determination for target cell binding
- Real-time kinetics on cells
- Advanced developability studies
- Off-target screens
- Cell-based functional assays
Lead Candidate Risk Assessment and Mitigation
- 1-2 Molecules
- Preformulation studies
- Storage stability studies
- Accelerated stability
- Viscosity determination
Preclinical Liquid Formulation Development
- 1-2 Molecules
- Liquid formulation development
- High-concentration formulation development
- Small-scale manual filling for downstream tests
With Quality and Reliability from Bench to Clinic
At 2bind, we empower biotech and pharma innovators with support before, during and after lead selection.
Our approach combines deep scientific expertise, high-end equipment, and a strong commitment to reliable, trusted and fast turnaround with minimal sample consumption — making us a premium partner for research related to early antibody development.
Therapeutic Antibody Research
Small-Scale Antibody Production
Efficient and scalable antibody expression is the foundational backbone of modern biotherapeutic development, directly driving critical milestones from initial lead selection to subsequent preformulation and formulation studies. We support our clients with a streamlined, small-scale expression and purification platform engineered to bridge the gap between digital sequence data and physical functional characterization.
Using state-of-the-art methodologies, we balance minimal material consumption with maximum yield generation. Every batch undergoes quality control to ensure consistent purity, correct folding, and batch-to-batch reproducibility. This highly parallelized setup allows you to evaluate dozens of candidates simultaneously under identical conditions. Whether you need to fuel early screening campaigns or generate reliable material for downstream developability assessments, our tailored solutions deliver the precise antibody quantities required to accelerate your discovery timelines and confidently de-risk your therapeutic pipeline.
Therapeutic Antibody Research
Screening Phase
We are committed to providing data enabling solid decisions that will not be questioned during project progression. We developed our platform in a way that balances material consumption and information gain.
During the screening phase we apply assays that use minimal amounts of material while delivering a comprehensive overview of binding and developability characteristics for each candidate. Our processes ensure high-quality and reproducible data in high-throughput assays with short turnover times, thereby improving and accelerating decision-making.
Therapeutic Antibody Research
Lead Selection
Deciding on the final lead out of a pool of promising candidates can be a challenge and the better the candidates the more the decision makers will be spoilt for choice. At this stage we recommend extending the characterization and including methods that are higher in material consumption but deliver details that cannot be resolved in the high throughput methods. Furthermore, we suggest keeping an eye on the physiological situation and assessing affinities under avidity-allowing and avidity-excluding conditions plus analyzing real-time kinetics of target cell binding – if of relevance.
At this important stage of the project, we implement off-target screens to flag potential issues which are easily overlooked and can cause costly failures in the clinic. We are equipped with a BSL2 cell culture lab and cell based functional assays can be implemented according to the project’s requirements.
Therapeutic Antibody Research
Lead Candidate Risk Assessment and Mitigation
Once decided for a lead candidate, questions about route of administration, formulation, concentration and storage conditions must be solved.
Our technologies and preformulation studies allow a preview and refinement of the room for maneuver. Our goal is to help you to understand any risk that might relate to certain lead candidates and identify ways to overcome these risks by appropriate formulations, concentrations or storage conditions.
Therapeutic Antibody Research
Preclinical Liquid Formulation Development
Transitioning a promising antibody candidate from discovery/development into early-stage toxicity and other preclinical tests requires more than just a stable molecule: it demands a robust, legally defensible formulation strategy. Our Preclinical Liquid Formulation Development Service is specifically engineered to de-risk this critical junction, bridging the gap between initial analytics and functionality and successful IND-filing documentation.
We believe that early-stage formulation development success is built on predictability, not unnecessary risk. That is why our approach relies strictly on conservative, industry-proven formulation strategies utilizing excipients and buffer systems well-characterized and accepted by the FDA. Instead of experimenting with unproven modalities, we focus on maximizing the potential of established frameworks.
Designed to deliver regulatory-accepted data while balancing material consumption and timeline efficiency, our platform is incorporated into our ISO 9001-certified quality management system (non-GMP).
We can adapt to your preferred route of administration and deal with high-concentration formulations for subcutaneous injections or low to medium concentration formulations for intravenously administered antibodies. We can work on antibodies, ADCs, bispecifics, nanobodies, conjugates, or mixtures.
To seamlessly support your subsequent in vivo studies, we offer flexible, small-scale manual filling services, ensuring the precise and secure preparation of your formulation batches for preclinical testing without wasting precious material.
With proven experience across diverse antigen classes and therapeutic antibody modalities, 2bind brings the speed, reliability, and scientific depth required to turn promising antibodies into clinic-ready candidates – while de-risking the path forward through early risk assessment and mitigation strategies.
Broad Expertise Across Antibody Modalities, Target Types and Disease Areas
Our antibody development services cover the full spectrum of therapeutic antibody modalities — from canonical full length IgGs and bispecific formats to antibody fragments and antibody-fusion proteins. Leveraging our high-end equipment and deep scientific expertise, we work across diverse target types, including membrane proteins, soluble proteins, and complex multiprotein systems. Whether your antibody is conventional or engineered for unique functions, we provide the processes, data quality, and speed to confidently advance your program.
Antibody Modalities
- IgG1, IgG2, IgG4, Fc-silenced IgG
- Bispecifics
- Multispecifics
- VHH/Nanobodies
- scFvs
- Fabs
- Antibody-fusion proteins
- ADCs
Mode of Actions
- ADCC, CDC, ADCP
- Ligand inhibition
- Agonist, antagonist
- T cell engagement
- Immune modulator
- Cytotoxicity
- Sweeping antibodies
Target Classes
- Membrane proteins
- Soluble proteins
- Multiprotein complexes
- Target cells
- Intrinsically Disordered Proteins / Amyloidogenic Proteins
Disease Areas
- Cancer
- Autoimmune diseases
- Infectious diseases
- Neurological disorders
- Metabolic diseases
- Cardiovascular diseases
Get in Touch!
"I’ve always been extremely satisfied with the service provided by 2bind. Communication has consistently been straightforward and uncomplicated, making collaborations very pleasant and efficient. The results and data we received were of high quality and fully trustworthy, which gave us great confidence in our decision-making. I happily recommend 2bind to anyone looking for reliable and professional support in their projects."
Johanna Gellert, PhD, Pentixapharm
Get In Touch
Planning a research project or interested in our analytical services? Get in touch with our team to discuss your requirements.
- +49 941 2000 0890
- info@2bind.com
- Im Gewerbepark D19a, 93059 Regensburg, Germany